Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 12:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 66 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: DPP-4 inhibitors Clear all
Terminated Phase 4 Interventional Results available

Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers

NCT02015910
View directory record Official record
Conditions
Type II Diabetes
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Sep 30, 2026, 12:57 AM EDT
Completed Phase 3 Interventional Results available

Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome

NCT00968708
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Acute Coronary Syndrome
Interventions
Alogliptin, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
5,380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
292
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 289 more
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Sep 30, 2026, 12:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PKs) of ZYDPLA1 Following Oral Administration in Healthy Volunteers

NCT02620592
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
ZYDPLA1 tablet, Placebo tablet
Drug
Lead sponsor
Zydus Lifesciences Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Sep 30, 2026, 12:57 AM EDT
Completed Phase 2 Interventional Results available

A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine

NCT03922750
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin glargine U100
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
13
States / cities
Walnut Creek, California • Roswell, Georgia • Idaho Falls, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Sep 30, 2026, 12:57 AM EDT
Not listed No phase listed Observational

BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

NCT05161429
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
DPP4, GLP-1 receptor agonist, Basal Insulin, SLGT2, SU
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
30 Years and older
Enrollment
550,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Wilmington, Delaware • Lexington, Kentucky • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Sep 30, 2026, 12:57 AM EDT
Completed Phase 3 Interventional Results available

The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)

NCT01137812
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Sitagliptin 100 mg, Canagliflozin 300 mg, Metformin, Sulphonylurea
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
85
States / cities
Mobile, Alabama • Goodyear, Arizona • Mesa, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 30, 2026, 12:57 AM EDT
Terminated Phase 4 Interventional Results available

Glycemia in Diabetic Elders Trial

NCT02029846
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Standard Treatment, Incretin-Based Treatment
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Sep 30, 2026, 12:57 AM EDT
Completed No phase listed Observational

Replication of the LEADER Diabetes Trial in Healthcare Claims

NCT03936049
View directory record Official record
Conditions
Diabetes
Interventions
Liraglutide, DPP-4 inhibitor
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years to 120 Years
Enrollment
168,690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 30, 2026, 12:57 AM EDT
Completed Phase 4 Interventional

Effects of Saxagliptin on Adipose Tissue Inflammation in Humans

NCT02285985
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
Phoenix VA Health Care System
Federal
Eligibility
21 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Sep 30, 2026, 12:57 AM EDT
Completed Phase 4 Interventional Results available

ADA Linagliptin in Long Term Care

NCT02061969
View directory record Official record
Conditions
Diabetes
Interventions
linagliptin, insulin glargine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Sep 30, 2026, 12:57 AM EDT
Completed Phase 2 Interventional

A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

NCT00111670
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
DPP-IV Inhibitor, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
18
States / cities
Salinas, California • Clearwater, Florida • Hialeah, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Sep 30, 2026, 12:57 AM EDT
Completed Phase 4 Interventional Results available

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

NCT02741687
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Sep 30, 2026, 12:57 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes Mellitus

NCT00690638
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PHX1149T, Placebo
Drug
Lead sponsor
Phenomix
Industry
Eligibility
18 Years to 85 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
13
States / cities
Norwalk, California • Orange, California • Santa Ana, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2010 · Synced Sep 30, 2026, 12:57 AM EDT
Completed Phase 4 Interventional Results available

Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients

NCT02024477
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
George Washington University
Other
Eligibility
40 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Sep 30, 2026, 12:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

NCT01413542
View directory record Official record
Conditions
Hypertension, Diabetes Type 2
Interventions
Sitagliptin (DPP4 inhibitor), Substance P,, bradykinin, enalaprilat (ACE inhibitor), Glucagon-like peptide 1, brain natriuretic peptide
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Sep 30, 2026, 12:57 AM EDT
Completed Phase 3 Interventional Results available

Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment

NCT00614939
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
11
States / cities
Concord, California • Sacramento, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 19, 2011 · Synced Sep 30, 2026, 12:57 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

NCT01106651
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin 100 mg, Canagliflozin 300 mg, Antihyperglycemic agent(s), Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
55 Years to 80 Years
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
34
States / cities
Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Sep 30, 2026, 12:57 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient

NCT02182895
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Saxagliptin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 110 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Sep 30, 2026, 12:57 AM EDT
Completed No phase listed Observational

Replication of the DECLARE Diabetes Trial in Healthcare Claims

NCT04215523
View directory record Official record
Conditions
Diabetes
Interventions
Dapagliflozin, DPP-4 inhibitor
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
49,790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 30, 2026, 12:57 AM EDT
Completed No phase listed Observational Results available

Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk

NCT05214573
View directory record Official record
Conditions
Type 2 Diabetes, Cardiac Disease
Interventions
Glucagon like peptide 1 receptor agonist, Sodium-glucose cotransporter 2 inhibitor, Dipeptidyl Peptidase 4 Inhibitor, Sulfonylurea
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
386,301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Sep 30, 2026, 12:57 AM EDT
Completed Phase 2 Interventional Results available

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

NCT03951805
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin Glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Anaheim, California • Lancaster, California • Roswell, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Sep 30, 2026, 12:57 AM EDT
Completed Phase 4 Interventional Results available

Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM

NCT01856907
View directory record Official record
Conditions
Disorder of Glucose Regulation
Interventions
Sitagliptin-Metformin, Metformin, Placebo pill
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 30, 2026, 12:57 AM EDT
Completed No phase listed Observational

Replication of the CANVAS Diabetes Trial in Healthcare Claims

NCT03936010
View directory record Official record
Conditions
Diabetes
Interventions
Canagliflozin, DPP-4 inhibitor
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
152,202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 30, 2026, 12:57 AM EDT
Completed Phase 3 Interventional Results available

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

NCT01794143
View directory record Official record
Conditions
Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
Interventions
Sulfonylurea (glimepiride), DPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist (liraglutide), Insulin (glargine)
Drug
Lead sponsor
GRADE Study Group
Other
Eligibility
30 Years and older
Enrollment
7,850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 30, 2026, 12:57 AM EDT